SCHEMBL696139

SCHEMBL696139

O=COC1(c2cccc(Cl)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 6/20 0.42
SLC6A4 P31645 5/20 0.42
SLC6A2 P23975 4/20 0.40
DPP4 P27487 2/20 0.39
CCR2 P41597 1/20 0.38
HTR2C P28335 2/20 0.36
HTR2A P28223 1/20 0.36
HTR2B P41595 1/20 0.36
HSD11B1 P28845 2/20 0.36
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
CHRNA1 P02708 2/20 0.33
CHRNG P07510 2/20 0.33
CHRNB1 P11230 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL697388 0.79 ALDH1A1 (0.41) SLC6A3SLC6A4SLC6A2HSD11B1PIM1
SCHEMBL75311 0.77 HSD17B10 (0.38) SLC6A3SLC6A4HSD11B1
SCHEMBL348386 0.77 MEN1 (0.39) MEN1KMT2A
SCHEMBL700240 0.76 SLC6A4 (0.42) SLC6A3SLC6A4SLC6A2
SCHEMBL28649793 0.75 PARP1 (0.43) SLC6A3SLC6A4SLC6A2DPP4CCR2
SCHEMBL3906658 0.74 SLC6A3 (0.45) SLC6A3SLC6A4SLC6A2DPP4CCR2
SCHEMBL5182694 0.72 SLC6A4 (0.44) SLC6A3SLC6A4SLC6A2HTR2CHTR2A
SCHEMBL31375623 0.71 SLC6A4 (0.46) SLC6A3SLC6A4SLC6A2DPP4CCR2
SCHEMBL3741976 0.71 SLC6A3 (0.42) SLC6A3SLC6A4SLC6A2HSD11B1
SCHEMBL13107026 0.71 SLC6A4 (0.46) SLC6A3SLC6A4SLC6A2DPP4CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 SLC6A3 1543/4885SLC6A4 985/4885SLC6A2 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.